1 appendix e-3
Analysis of soluble interleukin-2 receptor as cerebrospinal fluid biomarker for neurosarcoidosis
Carolin Otto, Oliver Wengert, Nadine Unterwalder, Christian Meisel, Klemens Ruprecht
Association of CSF sIL-2R with clinical and radiological disease activity as well as the CSF cell count in patients with neurosarcoidosis
active
remission 0
500 1000 1500 2000 2000 8000
sIL2R CSF (U/ml)
***
active
remission
active 0
500 1000 1500 2000
sIL-2R CSF (U/ml)
+ -
0 500 1000 1500 2000 2000 7000
sIL2R CSF (U/ml)
Diffuse leptomeningeal gd enhancement
*
0 50 100 150
0 500 1000 1500 2000 2000 8000
CSF cells/µl
sIL-2R CSF (U/ml)
n = 42 r = 0.8 p < 0.0001
A B
C D
2 (A) CSF sIL-2R in samples from patients with neurosarcoidosis obtained during clinically active disease (n = 15) or during clinical remission (n = 27). (B)
Intraindividual course of CSF sIL-2R in patients with neurosarcoidosis that underwent 2 (n = 5) or 3 (n = 2) sequential lumbar punctures during clinically active disease phases and clinical remission. (C) CSF sIL-2R in samples from patients with neurosarcoidois with (+; n = 11) or without (-; n = 4) diffuse leptomeningeal
gadolinium enhancement on MRI. (D) Correlation of CSF sIL-2R and CSF cell counts in samples from patients with neurosarcoidosis (n = 42). Results of Spearman’s rank analysis are shown.
*p < 0.05
***p < 0.0005
CSF = cerebrospinal fluid; gd = gadolinium; n = number of data pairs available for analysis; r = Spearman’s rho; sIL-2R = soluble interleukin-2 receptor
3 Association of the sIL-2R CSF/serum quotient (QsIL-2R) with clinical and
radiological disease activity as well as the CSF cell count in patients with neurosarcoidosis
active
remission 0
2000 4000 6000 8000
QsIL-2R× 103
***
active
remision
active 0
1000 2000 3000 4000
QsIL-2R× 103
+ -
1 10 100 1000 10000
QsIL-2R× 103
Diffuse leptomeningeal gd enhancement
*
0 50 100 150
0 500 1000 1500 2000 2000 8000
CSF cells/µl QsIL-2R× 103
n = 42 r = 0.75 p < 0.001
A B
C D
(A) QsIL-2R in samples from patients with neurosarcoidosis obtained during clinically active disease (n = 15) or during clinical remission (n = 27). (B) Intraindividual course of QsIL-2R in patients with neurosarcoidosis that underwent 2 (n = 5) or 3 (n = 2)
sequential lumbar punctures during clinically active disease phases and clinical remission. (C) QsIL-2R in samples from patients with neurosarcoidois with (+; n = 11) or
4 without (-; n = 4) diffuse leptomeningeal gadolinium enhancement on MRI. (D)
Correlation of QsIL-2R and CSF cell counts in samples from patients with neurosarcoidosis (n = 42). Results of Spearman’s rank analysis are shown.
*p < 0.05
***p < 0.0005
CSF = cerebrospinal fluid; gd = gadolinium; n = number of data pairs available for analysis; r = Spearman’s rho; QsIL-2R = sIL-2R CSF/serum quotient